Research Paper Volume 13, Issue 1 pp 1212—1235

Therapeutic potential of targeting HSPA5 through dual regulation of two candidate prognostic biomarkers ANXA1 and PSAT1 in osteosarcoma

High ANXA1 expression and low HSPA5 expression are involved in good outcomes of OS patients. (A–C) Box plots showing differential mRNA levels of ANXA1 and HSPA5 between sarcoma and normal tissues from ONCOMINE database. (D) The correlation of HSAP5 expression with the overall survival of sarcoma patients shown in Kaplan-Meier curve from KM plotter database. (E, F) The correlation of HSAP5 expression with the overall survival (69 cases) and progression free survival (63 cases) of OS patients shown in Kaplan-Meier curves from TARGET

Figure 6. High ANXA1 expression and low HSPA5 expression are involved in good outcomes of OS patients. (AC) Box plots showing differential mRNA levels of ANXA1 and HSPA5 between sarcoma and normal tissues from ONCOMINE database. (D) The correlation of HSAP5 expression with the overall survival of sarcoma patients shown in Kaplan-Meier curve from KM plotter database. (E, F) The correlation of HSAP5 expression with the overall survival (69 cases) and progression free survival (63 cases) of OS patients shown in Kaplan-Meier curves from TARGET_OS dataset. (G, H) Kaplan-Meier analyses of overall survival (in 81 cases) and progression free survival (in 77 cases) were conducted to show OS patients with lower ANXA1 mRNA level live shorter from TARGET_OS dataset.